Search research articles
Contact Us
Filters
Showing results (31-40 of 76) with videos related to
Page
of 8
Sort By:
Arthritis Research & Therapy
|
September 9, 2023
Treatment patterns and clinical outcomes in patients with rheumatoid arthritis initiating etanercept, adalimumab, or Janus kinase inhibitor as first-line therapy: results from the real-world CorEvitas RA Registry
Dimitrios A Pappas, Jacqueline O'Brien, Lin Guo, et al.
ACR Open Rheumatology
|
September 29, 2020
Maintenance of Sustained Low Disease Activity or Remission in Patients With Rheumatoid Arthritis Treated With Etanercept Monotherapy: Results from the Corrona Registry
Dimitrios A Pappas, Ying Shan, Tamara Lesperance, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
July 26, 2019
Machine Learning to Predict Anti-Tumor Necrosis Factor Drug Responses of Rheumatoid Arthritis Patients by Integrating Clinical and Genetic Markers
Yuanfang Guan, Hongjiu Zhang, Daniel Quang, et al.
Arthritis Care & Research
|
May 7, 2020
Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis
Jeffrey R Curtis, J Lynn Palmer, George W Reed, et al.
Arthritis Care & Research
|
September 22, 2025
Development and External Validation of a Multivariable Predictive Model for Progression to Difficult-to-Treat Rheumatoid Arthritis in Biologic-Experienced Patients
Misti L Paudel, Nancy Shadick, Michael Weinblatt, et al.
Arthritis Care & Research
|
May 29, 2015
Herpes Zoster Reactivation in Patients With Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease-Modifying Antirheumatic Drugs
Dimitrios A Pappas, Michele M Hooper, Joel M Kremer, et al.
Rheumatology International
|
September 3, 2020
Persistence on biologic DMARD monotherapy after achieving rheumatoid arthritis disease control on combination therapy: retrospective analysis of corrona registry data
Dimitrios A Pappas, Heather J Litman, Tamara Lesperance, et al.
The Journal of Rheumatology
|
February 15, 2024
Treatment Patterns and Effectiveness of Tofacitinib in Patients Initiating Therapy for Rheumatoid Arthritis: Results From the CorEvitas Rheumatoid Arthritis Registry
Dimitrios A Pappas, Jacqueline O'Brien, Page C Moore, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases
|
March 31, 2023
Meaningful Improvement and Worsening in Patients Who Do Not Achieve Low Disease Activity and Switch Therapy to a New Biologic or Targeted Disease-Modifying Antirheumatic Drug: Results From the CorEvitas RA Registry
Jeffrey R Curtis, Stefano Fiore, Kerri Ford, et al.
The Journal of Rheumatology
|
December 16, 2020
The Clinical Disease Activity Index and the Routine Assessment of Patient Index Data 3 for Achievement of Treatment Strategies
Joel M Kremer, Dimitrios A Pappas, Kevin Kane, et al.
Page
of 8
Search research articles
Search
Showing results (31-40 of 76) with videos related to
Sort By:
Page
of 8
Arthritis Research & Therapy
|
September 9, 2023
Treatment patterns and clinical outcomes in patients with rheumatoid arthritis initiating etanercept, adalimumab, or Janus kinase inhibitor as first-line therapy: results from the real-world CorEvitas RA Registry
Dimitrios A Pappas, Jacqueline O'Brien, Lin Guo, et al.
ACR Open Rheumatology
|
September 29, 2020
Maintenance of Sustained Low Disease Activity or Remission in Patients With Rheumatoid Arthritis Treated With Etanercept Monotherapy: Results from the Corrona Registry
Dimitrios A Pappas, Ying Shan, Tamara Lesperance, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
July 26, 2019
Machine Learning to Predict Anti-Tumor Necrosis Factor Drug Responses of Rheumatoid Arthritis Patients by Integrating Clinical and Genetic Markers
Yuanfang Guan, Hongjiu Zhang, Daniel Quang, et al.
Arthritis Care & Research
|
May 7, 2020
Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis
Jeffrey R Curtis, J Lynn Palmer, George W Reed, et al.
Arthritis Care & Research
|
September 22, 2025
Development and External Validation of a Multivariable Predictive Model for Progression to Difficult-to-Treat Rheumatoid Arthritis in Biologic-Experienced Patients
Misti L Paudel, Nancy Shadick, Michael Weinblatt, et al.
Arthritis Care & Research
|
May 29, 2015
Herpes Zoster Reactivation in Patients With Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease-Modifying Antirheumatic Drugs
Dimitrios A Pappas, Michele M Hooper, Joel M Kremer, et al.
Rheumatology International
|
September 3, 2020
Persistence on biologic DMARD monotherapy after achieving rheumatoid arthritis disease control on combination therapy: retrospective analysis of corrona registry data
Dimitrios A Pappas, Heather J Litman, Tamara Lesperance, et al.
The Journal of Rheumatology
|
February 15, 2024
Treatment Patterns and Effectiveness of Tofacitinib in Patients Initiating Therapy for Rheumatoid Arthritis: Results From the CorEvitas Rheumatoid Arthritis Registry
Dimitrios A Pappas, Jacqueline O'Brien, Page C Moore, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases
|
March 31, 2023
Meaningful Improvement and Worsening in Patients Who Do Not Achieve Low Disease Activity and Switch Therapy to a New Biologic or Targeted Disease-Modifying Antirheumatic Drug: Results From the CorEvitas RA Registry
Jeffrey R Curtis, Stefano Fiore, Kerri Ford, et al.
The Journal of Rheumatology
|
December 16, 2020
The Clinical Disease Activity Index and the Routine Assessment of Patient Index Data 3 for Achievement of Treatment Strategies
Joel M Kremer, Dimitrios A Pappas, Kevin Kane, et al.
Page
of 8